Gilead Sciences (NASDAQ:GILD)

automatic inspection machine

5 Top Biotechs Where Future Multi-Billion Dollar Drug Pipelines are Valued Almost at Zero

Sometimes market volatility and outside shocks create a rift between market prices and real value. That may currently be the case in the largest stocks in the biotech sector within health ...
Read Full Story »
biotech word cloud

Short Sellers Run for Cover From Major Biotechs

The short interest data are out for the June 15 settlement date. Biotech companies are considered a riskier group of stocks, with big potential upside and big potential downside. After ...
Read Full Story »
Dollar Sign Island

20 Companies Buying Back the Most Stock in 2016

It is no secret that investors love dividends and stock buybacks. In recent years, there has been a larger shift into companies buying back shares of common stock, even while they ...
Read Full Story »
graph

Gilead Sciences Bounces on Preliminary Results

Shares of Gilead Sciences Inc. (NASDAQ: GILD) saw make a handy gain just off of their 52-week low following the release of preliminary data from its HIV treatment. After the stock dropped ...
Read Full Story »
biotech word cloud

Short Sellers Become More Selective on Major Biotechs

The short interest data are out for the May 31 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
mosquito

7 Companies in the Fight to Defeat the Zika Virus

In 2016, it is the Zika virus that has the public worried about the next pandemic. Past scares have been around Ebola, E. coli, SARS, mad cow, swine flu and ...
Read Full Story »
Test tubes

Short Sellers Grow More Selective on Major Biotechs

The short interest data are out for the May 13 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
Stock Price

The 52-Week Low Club for Thursday

May 19, 2016: Here are four stocks trading with heavy volume among 81 equities making new 52-week lows in Thursday's session. NYSE decliners led advancers by nearly 2 to 1 ...
Read Full Story »
Test tubes

Short Sellers Run for Cover From Major Biotechs

The short interest data are out for the April 29 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
graph

Can Gilead Shares Still Really Rise to $150?

Gilead Sciences Inc. (NASDAQ: GILD) recently saw a sell-off after the company posted less than favorable earnings, but one analyst thinks that investors have spoken too soon. This independent analyst ...
Read Full Story »
biotech word cloud

Analysts Make Major Changes to Top Biotech Ratings

At different times of the year, certain sectors come alive or slow down. Typically each year, the first quarter is the slowest for the biotechs, so many analysts tend to ...
Read Full Story »
ThinkstockPhotos-475472230

Top Analyst Upgrades and Downgrades: Amazon, Ford, Gilead, Level 3, Sarepta, Western Digital, Whiting Petroleum and More

Stocks had a rough Thursday and futures were indicated lower on Friday. Despite the drop, we have yet to see any serious selling pressure in a while and investors still ...
Read Full Story »
clinical trials

Gilead Results Trip Over Both the Top and Bottom Lines

Gilead Sciences Inc. (NASDAQ: GILD) reported first-quarter financial results after the markets closed on Thursday. The company had $3.03 in earnings per share (EPS) on $7.79 billion in revenue compared ...
Read Full Story »
biotech word cloud

Short Sellers Run for Cover From Major Biotechs

The short interest data are out for the April 15 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
Prescription Drugs, Pills

The World’s 15 Top Selling Drugs

Attaining a certain drug can mean the difference between life and death for millions of Americans. These essential products also help generate billions for drug manufacturers. Pharmaceutical companies generate an ...
Read Full Story »